Novotech

At Novotech, we champion equal pay for equal work, irrespective of gender. We recognize that closing gender pay gaps strengthens our workforce, benefits our customers, and enhances the communities we serve globally. This International Equal Pay Day, we renew our pledge to compensate employees based on their skills and contributions, not their gender. While legal frameworks and social norms vary across our operating countries, our values remain constant. We conduct thorough pay equity reviews, implement family-friendly policies, and foster career growth for all employees. Our CEO, Dr. John Moller, and all of our leadership team are passionate about this cause and at Novotech we will always strive to promote activities and initiatives that support our inclusive culture. Our goal is to lead by example in pay equality as we work towards eliminating the gender pay gap entirely.

#Novotech has been awarded the Brandon Hall Gold Award for our CRA Monitoring Simulation Program, recognized for its excellence in developing key competencies and hands-on training. This program ensures our Clinical Research Associates are equipped with the critical skills needed to manage clinical trials effectively, ultimately supporting the delivery of life-saving therapies to market. The award reflects our commitment to quality and innovation in training, helping drive success for both our clients and the broader medical research community. Discover more about how Novotech is advancing clinical trial excellence by visiting our website: https://lnkd.in/divNK9mq #Triaining #BrandonHall #CRA

Celebrating Mid-Autumn Festival at Novotech China! Our China team is coming together to honor the Mid-Autumn Festival, one of the most important traditional festivals in China. The office is filled with festive joy as we prepare for September 17th! Beautifully decorated mooncakes, vibrant flowers, and creative activities bring the spirit of reunion and gratitude to life. Our celebration showcases Novotech's commitment to local cultures and our warm, inclusive workplace. Happy Mid-Autumn Festival! #MidAutumnFestival #NovotechChina #lifeatnovotech

#Novotech has been honored with the distinguished 2024 Global Biotech Contract Research Organization Company of the Year Award by Frost & Sullivan. This recognition comes as a result of our commitment to accelerating clinical development for #biotech companies through innovative solutions, advanced analytics, and a global presence. After establishing a dominant presence in the APAC CRO market, recognized as the most complex clinical trial region globally, Novotech strategically expanded its geographic footprint into the US and European markets. "Novotech distinguishes itself in the ever-expanding CRO market by successfully addressing the complex regulatory landscape with a deep understanding of local regulations and overcoming cultural barriers to establish itself as a truly global CRO," says Unmesh Lal, Global Research Director at Frost & Sullivan. "We are honored to receive the 2024 Global Company of the Year Award from Frost & Sullivan," said Dr. John Moller, CEO of Novotech. "This recognition is a testament to the hard work and dedication of our team, our commitment to innovation, and our unwavering focus on delivering exceptional results for our biotech and pharmaceutical clients. We are proud to be at the forefront of advancing clinical development and to be acknowledged as a leader in the industry.” https://lnkd.in/dxFEdtdG #GlobalClinicalResearch #GlobalCRO

As the full harvest moon rises, we're shining a spotlight on Chuseok, a cherished Korean holiday that some of our team members are celebrating! Often called "Korean Thanksgiving," Chuseok is a time when families reunite to share sumptuous meals, ancestors are honored in heartfelt ceremonies and gratitude flows for the bountiful harvest. At Novotech, our strength lies in the rich tapestry of cultures woven by our global team. By embracing and understanding each other's traditions, we forge stronger bonds and broaden our perspectives. Whether Chuseok is part of your heritage or new to you, we invite you to reflect on its universal themes of gratitude, family, and community. #Chuseok #CulturalDiversity

#DidYouKnow Worldwide, Pancreatic Cancer (PC) ranks 12th in terms of total cancer incidence and 6th in cancer-related deaths? With a 5-year survival rate is between 2%-10%, PC has become a priority for the development of innovative treatment research. The future of PC treatment appears promising, with advancements in personalized medicine, early detection methods, and targeted biological therapies on the horizon. You can discover key insights into the current state and the latest advancements in PC research through the in-depth disease analysis provided in Novotech’s report, available for free download via this link: https://lnkd.in/dwHbnSRt #ClinicalResearch #PancreaticCancer #PDAC

Celebrate What Matters to You Choose alternate dates for allocated holidays that align with your culture. We support you in observing the celebrations that are most meaningful to you. Follow us to learn more about at Novotech #lifeatnovotech #cra #clinicaltrials #clinicalresearch #clinicalresearchassociate #cro

We are thrilled to invite you to an upcoming webinar titled "Empowering Patients to Overcome Challenges in Orphan Drug Development" on Thursday, 26 September 2024, at 15:00 CEST (9am EST / 9pm CST). This #webinar is a valuable opportunity for professionals in the medical research and clinical trials sector, particularly those working in rare disease and orphan drug development. Led by industry experts, the session will explore practical strategies and patient-centered approaches to advance orphan drug research. Key topics include: 🔹 Challenges and opportunities in the orphan drug market. 🔹 Patient-focused drug development strategies to improve trial engagement and reduce burden. 🔹 Operational considerations, including endpoint selection and cost management. 🔹 The importance of collaboration among sponsors, CROs, and patient advocacy groups. The event will be moderated by Scott Schliebner, Vice President of Clinical Development Consulting at Novotech, who will guide the discussion and ensure a dynamic exchange of ideas. Register now to join this important conversation and gain insights that can transform your approach to orphan drug development: https://lnkd.in/dJ3hiB5s Panelists: Scott Schliebner, VP- Drug Development Consulting, Novotech Afshawn C. ,Director, Program Management, Avidity Biosciences, Inc. Michal Meller, Project Management Director, Novotech Lauren Dahl, Senior Operations Manager, leapcure Ella Balasa, Patient Advocate, Consultant, Balasa Consulting We look forward to seeing you there. #OrphanDrugDevelopment #RareDiseaseResearch #Novotech

#DidYouKnow Gastric cancer (GC) ranks as the fifth most diagnosed cancer and the leading cause of cancer mortality? Since 2019, over 2,000 clinical trials have been initiated globally to explore new treatments. The focus is shifting from traditional chemotherapy to personalized approaches, including targeted therapies and immunotherapy. Advances in molecular diagnostics and biomarkers are paving the way for precision medicine. Ongoing research and collaboration are crucial for enhancing early detection, reducing recurrence, and optimizing GC treatments. You can discover key insights into the current state of GC research through the in-depth disease analysis provided in Novotech’s report, available for free download via this link: https://lnkd.in/dEEDZiQV #GastricCancer #PrecisionMedicine #CancerResearch

On Global Talent Acquisition Day, we celebrate Novotech's exceptional TA team! They don't just find talent; they create outstanding experiences for every candidate they meet. Their dedication to connecting great people with great opportunities while ensuring a positive journey is truly commendable. Thank you for being the friendly faces of Novotech and for your commitment to both our company and our candidates! #TalentAcquisitionDay #Lifeatnovotech #ClinicalTrials